



SOLARA
Active Pharma Sciences

Communication Address :
Solara Active Pharma Sciences Limited
Batra Centre
No. 28, Sardar Patel Road, Post Box 2630
Guindy, Chennai - 600 032, India
Tel : +91 44 43446700, 22207500
Fax : +91 44 22350278

January 09, 2020

The BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai - 400 001
Scrip Code: 541540

The National Stock Exchange of India
Limited Exchange Plaza, Bandra-Kurla
Complex Sandra (E), Mumbai - 400 051
Scrip Code: SOLARA

Dear Sir/ Madam,

Subject: Update on Nizatidine Capsules

We understand from Mylan N.V.'s press release¹ dated January 08, 2020, that Mylan N.V.'s U.S. based Mylan Pharmaceuticals(Mylan) has initiated a voluntary recall of three lots of Nizatidine Capsules, USP (150mg and 300mg strengths) due to detected trace amounts of impurity N-nitrosodimethylamine (NDMA) contained in the Nizatidine API. Mylan also indicated that the recall is voluntary, and the Company has not received any reports of adverse events related to these batches to date.

We are in the process of collecting corresponding lots of API from Mylan to carry out our internal investigation.

We would further inform you that our last supplies of Nizatidine API to Mylan were made in September 2017 and our overall sales of this API to the US market are less than 0.1% of our total Company revenues.

We do not foresee any significant impact on the growth trajectory of the Company, and any further improvements / updates in this regard will be intimated to Stock Exchanges.

Thanking you,
Yours faithfully,

For Solara Active Pharma Sciences Limited


S. Murali Krishna
Company Secretary



¹ <http://newsroom.mylan.com/2020-01-08-Mylan-Initiates-Voluntary-Nationwide-Recall-of-Three-Lots-of-Nizatidine-Capsules-USP-Due-to-the-Detection-of-Trace-Amounts-of-NDMA-N-Nitrosodimethylamine-Impurity-Found-in-the-Active-Pharmaceutical-Ingredient-Manufactured-by-Solara-Active-Pharm>